HSBC TUR.WAR.OP.END. CPW/ DE000HS2VA78 /
| 5/28/2024 9:37:13 PM | Chg.-0.0400 | Bid9:59:33 PM | Ask9:59:33 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.1400EUR | -22.22% | 0.1300 Bid Size: 300,000 |
0.1400 Ask Size: 300,000 |
Check Point Software... | 136.3195 USD | 12/31/2078 | Call |
GlobeNewswire
10:15 PM
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire
4:40 PM
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with...
GlobeNewswire
4:20 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire
2:00 PM
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
GlobeNewswire
12:30 PM
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Tril...
GlobeNewswire
9:00 AM
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
GlobeNewswire
5/27
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel...
GlobeNewswire
5/27
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
5/24
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenaden...
GlobeNewswire
5/23
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire
5/23
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
GlobeNewswire
5/23
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at A...
GlobeNewswire
5/23
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Adva...
GlobeNewswire
5/23
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study i...
GlobeNewswire
5/23
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combinatio...
GlobeNewswire
5/23
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire
5/23
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual M...
GlobeNewswire
5/23
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Adv...
GlobeNewswire
5/23
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monothera...
GlobeNewswire
5/23
CKPT SHAREHOLDER ALERT: TOP RANKED ROSEN LAW FIRM Encourages Checkpoint Therapeutics, Inc. Investors...
GlobeNewswire
5/23
Holzer & Holzer, LLC Reminds Shareholders of June 4, 2024 Lead Plaintiff Deadline in Checkpoint Ther...
GlobeNewswire
5/22
SHAREHOLDER ALERT Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint
GlobeNewswire
5/22
DEADLINE ALERT for HRT and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions...
